Amundi Cure Vac N.V. Transaction History
Amundi
- $264 Billion
- Q3 2024
A detailed history of Amundi transactions in Cure Vac N.V. stock. As of the latest transaction made, Amundi holds 122,357 shares of CVAC stock, worth $310,786. This represents 0.0% of its overall portfolio holdings.
Number of Shares
122,357
Previous 97,379
25.65%
Holding current value
$310,786
Previous $331,000
8.46%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding CVAC
# of Institutions
92Shares Held
12.3MCall Options Held
164KPut Options Held
117K-
Israel Englander Millennium Management LLC | New York, Ny2.42MShares$6.14 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.25MShares$5.72 Million0.0% of portfolio
-
Bill & Melinda Gates Foundation Seattle, WA1.57MShares$3.98 Million10.6% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.01MShares$2.57 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct780KShares$1.98 Million0.01% of portfolio
About CureVac N.V.
- Ticker CVAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,467,008
- Market Cap $476M
- Description
- CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...